Background: Hearing loss is common in older adults. Screening could identify untreated hearing loss and lead to interventions to improve hearing-related function and quality of life.
Editor's Note: As part of the U.S. Preventive Services Task Force's (USPSTF) ongoing commitment to clarity about its work and methods, the USPSTF is inviting public comment on all draft recommendation statements. The USPSTF's draft recommendation statement on screening adults aged 50 years or older
for hearing loss will soon be available for public comment at www.uspreventiveservicestaskforce.org/tfcomment.htm. As a result, the recommendation on screening adults aged 50 years or older for hearing loss does not appear with this accompanying background review. Once finalized, the recommendation statement will reflect any changes made on the basis of the public comments received. A summary of these changes will be included in a new section of the final recommendation statement.
T he prevalence of hearing loss is 20% to 40% in adults aged 50 years or older and more than 80% for those aged 80 years or older (1) (2) (3) (4) . Hearing loss can affect quality of life and ability to function (5) . Age-related hearing loss (presbycusis) is typically gradual, progressive, and bilateral (1) . Other factors contributing to hearing loss in older adults include genetic factors, exposure to loud noises, exposure to ototoxic agents, history of inner ear infections, and presence of systemic diseases (such as diabetes mellitus) (6 -8) .
Older adults may not realize that they have hearing loss because it is relatively mild or slowly progressive; they may perceive hearing loss but not seek evaluation for it; or they may have difficulty recognizing or reporting hearing loss owing to comorbid conditions, such as cognitive impairment. Only 10% to 20% of older adults with hearing loss have ever used hearing aids (2, 9) . Screening could identify people who could benefit from therapies for hearing loss.
In 1996, the USPSTF issued a recommendation to screen adults aged 50 years or older for hearing loss (grade B recommendation) (10) . In 2009, the USPSTF commissioned a new evidence review to update its recommendation. The purpose of this report is to systematically evaluate the current evidence on screening for hearing loss in adults aged 50 years or older in primary care settings. (The full evidence review [11] is available on the USPSTF Web site, www.uspreventiveservicestaskforce .org.) The key questions, analytic framework (Appendix Figure, available at www.annals.org), and scope of the report were developed in accordance with previously published USPSTF processes and methods (12) (13) (14) . The key questions were:
1. Does screening of asymptomatic adults aged 50 years or older lead to improved health outcomes? "good," "fair," or "poor" by using predefined criteria developed by the USPSTF (Appendix Table 3 ) (14, 15) . We also evaluated the applicability of studies to primary care screening on the basis of whether patients were recruited from primary care settings, prevalence and severity of hearing loss, proportion of patients with perceived hearing loss, and access to hearing aids (such as availability of free hearing aids). We resolved discrepancies in quality ratings by discussion and consensus.
For diagnostic accuracy studies, we used the diagti procedure in Stata, version 10 (StataCorp, College Station, Texas), to calculate sensitivities, specificities, and likelihood ratios. For studies that reported diagnostic accuracy based on more than 1 definition of hearing loss, we estimated median values on the basis of the Ventry and Weinstein criteria (for Ͼ40-dB hearing loss), the Speech Frequency Pure-Tone Average criteria (for Ͼ25-dB hearing loss), or the definition most similar to those used by other relevant studies. We used the cci procedure in Stata to calculate diagnostic odds ratios with exact 95% CIs.
Data Synthesis and Analysis
We assessed the overall strength of the body of evidence for each key question ("good," "fair," or "poor") by using methods developed by the USPSTF on the basis of the number, quality, and size of studies; consistency of results among studies; and directness of evidence (14) . We did not quantitatively pool results on diagnostic accuracy because of differences across studies in populations evaluated, definitions of hearing loss, screening tests evaluated, and screening cutoffs applied. Instead, we created descriptive statistics with the median sensitivity, specificity, and likelihood ratios (16) , as well as associated ranges. We chose the total range, rather than the interquartile range, because certain outcomes were reported by only a few studies and the summary range highlights the greater uncertainty in the estimates. Too few randomized trials of hearing loss treatments were available to perform metaanalysis.
Role of the Funding Source
This study was funded by the Agency for Healthcare Research and Quality under a contract to support the work of the USPSTF. Agency staff and USPSTF members helped develop the scope of this work and reviewed draft manuscripts. Agency approval was required before this manuscript could be submitted for publication, but the authors are solely responsible for the content and the decision to submit it for publication.
RESULTS

Key Question 1
Does screening of asymptomatic adults aged 50 years or older for hearing loss lead to improved health outcomes?
We identified 1 randomized trial (17) of screening for hearing loss ( Rates of positive screenings were 19% in the AudioScope group, 59% in the HHIE-S group, and 64% in the combined group. Hearing aid use at 1 year, the primary outcome, was 6.3% in the AudioScope group, 4.1% in the HHIE-S group, 7.4% in the combined group, and 3.3% in the control group (P ϭ 0.03 for between-group difference). In a post hoc stratified analysis, hearing aid use was greater among patients with perceived hearing loss (5.7% to 9.6% in screened groups vs. 4.4% in control group), but hearing aid use was minimal regardless of screening status among patients without perceived hearing loss (0% to 1.6%).
The proportion of patients who had a minimum clinically important difference (Ն6-point improvement on a 0-to 100-point scale) on the Inner Effectiveness of Aural Rehabilitation scale (a measure of hearing-related function), a secondary outcome of the trial, did not differ at 1 year (36% to 40% in the screened groups vs. 36% in the unscreened group; P ϭ 0.39). Post hoc analyses also showed no differences in the proportion who had improvements in hearing-related function according to whether patients had perceived hearing loss, except in a subgroup that was also 65 years of age or older (54% in the AudioScope group, 34% in the HHIE-S group, 40% in the combined group, and 34% in the control group).
Key Question 2
How accurate are the hearing-loss screening methods among older adults, including questionnaires, clinical techniques (whispered voice test), and hand-held audiometry?
Twenty studies evaluated the diagnostic accuracy of various screening tests (Appendix Table 5 ) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) . Four studies evaluated clinical tests (23, 26, 31, 37) , 8 evaluated singlequestion screening (23, 25, 28, 33, 34, 36, 38, 40) , 9 evaluated a hearing questionnaire (28 -30, 32, 33, 35, 36, 39, 41) , and 6 evaluated a hand-held audiometric device (22, 24, 26, 27, 30, 32) . Four studies were population-based (25, 28, 33, 36) , 4 recruited patients from primary care or communitybased settings (30, 32, 35, 41) , and the remainder recruited patients from specialty or other high-prevalence settings or evaluated nursing-home residents (24, 40) .
We rated the quality of 7 studies as good (23, 25, 28, 30, 32, 33, 35) and the remainder as fair (Appendix Table  6 , available at www.annals.org). The most common methodological shortcomings were failure to describe a representative spectrum of patients, failure to report interpretation of the reference standard blinded to results of the screening test, and failure to describe a random or consecutive series of patients. All studies except for 1 used puretone audiometry as the reference standard, and 4 studies used a portable audiometer instead of standard audiometry (24, 34, 38, 40) . One study performed an audiometric examination but used an audiologist assessment as the reference standard (41) . Table 2 summarizes the main results on diagnostic accuracy.
Whispered Voice, Finger Rub, and Watch Tick Tests
One good-quality (23) and 3 fair-quality (26, 31, 37) studies evaluated the whispered voice test at 2 feet for identifying hearing loss greater than 25 or 30 dB (Appendix Table  7 ). Likelihood ratio (LR) estimates varied, with a median positive LR of 5.1 (range, 2.3 to 7.4) and median negative LR of 0.03 (range, 0.007 to 0.73). The good-quality study reported the weakest LRs (positive LR, 2.3 [95% CI, 1.3 to 3.8]; neg- 
NA (1 study) Low to moderate Fair
Summary of findings: One trial found that screening with the HHIE-S, the AudioScope, or both was associated with greater hearing aid use at 1 y compared with no screening. Effects of screening on hearing aid use seemed limited to patients with perceived hearing loss at baseline. Screening was not associated with any differences in hearing-related quality of life compared with no screening. Because three quarters of patients enrolled in the trial reported perceived hearing loss and all patients were eligible to receive free hearing aids, results are likely to be most generalizable to high-prevalence settings in which the cost of hearing aids is not a barrier. KQ 3: How efficacious is the treatment of (screen-detected) hearing loss, namely amplification, in improving health outcomes? 4 RCTs Only 1 good-quality trial of hearing aids vs. no hearing aids, conducted in a VA setting in patients eligible for free hearing aids.
Consistent Low to moderate Fair
Summary of findings: One good-quality RCT found that immediate hearing aids were associated with moderate improvements in hearing-specific quality of life and communication difficulties compared with wait-list control in veterans with hearing loss Ͼ40 dB who were eligible for free hearing aids. A smaller, fair-quality RCT found no clear difference between an assistive listening device and no treatment in veterans ineligible for free hearing aids. Another fair-quality RCT found no difference between a hearing aid, an assistive listening device, or both and no amplification in a subgroup of patients not using hearing aids at enrollment with mild baseline hearing loss and hearing-related handicap. A fourth RCT of hearing aids vs. no hearing aids reported outcomes very poorly. 
Single-Question Screening
Five good-quality (23, 25, 28, 33, 36 ) and 3 fair-quality (34, 38, 40) studies evaluated a single screening question about perceived hearing difficulties (Appendix Table 8 
Screening Questionnaires
Five good-quality (28, 30, 32, 33, 36 ) and 3 fairquality (35, 39, 41) studies evaluated the HHIE-S, and 1 fair-quality study evaluated the American Academy of Otolaryngology-Head and Neck Surgery 5-minute hearing test (29) (Appendix Table 9 ).
On the basis of an HHIE-S cutoff score greater than 8, 4 good-quality studies reported a median positive LR of 3.5 (range, 2.4 to 11) and negative LR of 0.52 (range, 0.43 to 0.70) for detection of hearing loss greater than 25 dB (30, 32, 33, 36) . One fair-quality study reported a somewhat lower positive LR and similar negative LR (2.3 and 0.38, respectively [CIs not calculable]) based on an audiologist evaluation reference standard rather than audiometry (41) . Studies on the accuracy of HHIE-S cutoff scores greater than 8 for identifying hearing loss greater than 40 dB reported similar likelihood ratios (28, 30, 32, 36, 39) . Changing the HHIE-S threshold from greater than 8 to greater than 24 increased the positive LR for identification of hearing loss greater than 40 dB from 3.1 to 10 and increased the negative LR from 0.37 to 0.77 in 1 good-quality study (30) but had little effect on LR estimates in another good-quality study (32) .
One fair-quality study found that the 5-minute hearing test had positive LRs ranging from 1.1 to 9.9 and negative LRs ranging from 0.47 to 0.76 for detection of hearing loss greater than 25 dB, depending on the cutoff score evaluated (29) .
Hand-Held Audiometric Devices
Two good-quality (30, 32) and 4 fair-quality (22, 24, 26, 27) studies evaluated the AudioScope hand-held audiometric device (Appendix Table 10 ). The frequencies and intensities of the tones tested with the AudioScope varied. For detection of hearing loss greater than 25 dB (based on Speech Frequency Pure-Tone Average criteria), 1 goodquality study found that the AudioScope (based on the ability to hear a 2000-Hz tone at 40 dB) had a positive LR of 5.8 (CI, 3.4 to 9.8) and a negative LR of 0.40 (CI not calculable) (32) . For detection of hearing loss greater than 30 dB, a fair-quality study found that the AudioScope (based on ability to hear 500-, 1000-, 2000-, and 4000-Hz tones at 25 dB) had a positive LR of 3.1 and a negative LR of 0.10 (CIs not calculable) (22) . For detection of hearing loss greater than 40 dB, 3 studies of community-dwelling older adults found that the AudioScope (based on ability to hear tones between 500 and 4000 Hz at 40 dB) had a median positive LR of 3.4 (range, 1.7 to 4.9) and median negative LR of 0.05 (range, 0.03 to 0.08) (26, 30, 32) . One fair-quality study of nursing-home residents found that the AudioScope (based on failure to hear a 1000-or 2000-Hz tone in both ears) was associated with a much weaker positive LR (1.3 [CI, 1.0 to 1.5]) but similar negative LR (0.08 [CI, 0.01 to 0.61]) (24) .
Direct Comparisons of Different Types of Screening Tests
Six good-quality studies directly compared the diagnostic accuracy of different screening tests (23, 28, 30, 32, 33, 36 (23) . Three studies showed a consistent tradeoff with the HHIE-S compared with singlequestion screening, with somewhat stronger positive and weaker negative LRs (23, 28, 33, 36) . Two studies found that normal results on AudioScope were generally associated with stronger negative LRs (0.05 and 0.24) compared with the HHIE-S (0.37 and 0.76), although LR estimates varied deClinical Guideline Screening Older Adults for Hearing Loss pending on the HHIE-S cutoff score evaluated and the criteria used to define hearing loss (30, 32) .
Key Question 3
How efficacious is the treatment of (screen-detected) hearing loss, namely amplification, in improving health outcomes?
We identified 4 RCTs on treatment of hearing loss (Table 1) (18 -21) . We rated the quality for 1 trial as good (19), 2 as fair (18, 21) , and 1 as poor (20) (Appendix Table 4) . Shortcomings of the fair-quality trials included potentially important baseline differences between groups and failure to describe intention-to-treat analysis (21) and failure to describe randomization or allocation concealment methods or loss to follow-up (18) . The poor-quality trial did not describe allocation concealment, use of intention-to-treat analysis, or loss to follow-up and reported outcomes incompletely (20) . All of the trials had characteristics that could limit generalizability to screening in primary care, including recruitment of mostly white male veterans (19, 21) , restriction to patients eligible for free hearing aids (21), inclusion of patients referred for suspected hearing problems (19) , enrollment of dependent older adults (20) , and inclusion of patients using hearing aids (18) .
The good-quality RCT (n ϭ 194) randomly assigned veterans (mean age, 72 years) to immediate hearing aids or wait-list control for 4 months (19) . About two thirds of patients were enrolled from a primary care setting on the basis of a positive AudioScope screening result for hearing loss greater than 40 dB. The others were referred to the trial because of suspected hearing problems. Mean pure-tone threshold was 52 dB and was similar among screening-detected and referred patients. Mean baseline HHIE score was about 50 (25 items; range, 0 to 100), indicating severe effects on hearing-related quality of life and function (42) .
At 4 months, HHIE or Quantified Denver Scale (QDS) (a measure of perceived communication difficulties) scores did not change from baseline in the control group. In the hearing aid group, the HHIE score improved from a mean of 49 at baseline to 15 at 4 months and the QDS score improved from 59 to 36. The mean betweengroup difference in change from baseline was 34 (CI, 27 to 41) on the HHIE and 24 (CI, 17 to 31) on the QDS. Results were similar in the subgroup of screening-detected patients. Statistically significant but small (Ͻ1 point) effects on the Geriatric Depression Scale (0-to 15-point scale) and Short Portable Mental Status Questionnaire (0-to 10-point scale) scores were also observed in the hearing aid group, but baseline scores indicated only mild depression or cognitive dysfunction. A follow-up study found that improvements in HHIE and QDS scores were sustained in the hearing aid group through 12 months (43) .
A second, fair-quality trial (n ϭ 64) enrolled veterans (mean age, 68 years) with less severe hearing loss (mean pure-tone threshold of 32 dB) (21) . Patients eligible for free VA-issued hearing aids (n ϭ 30) were randomly assigned to a standard nondirectional (n ϭ 14) or a programmable, directional digital hearing aid (n ϭ 16). Those ineligible for free hearing aids were randomly assigned to no treatment (n ϭ 15) or an assistive listening device (n ϭ 15). Baseline differences across the intervention groups in Abbreviated Profile of Hearing Aid Benefit (APHAB) score (0-to 100-point scale) were statistically significant (range, 38 to 52; P ϭ 0.04) and were likely to be clinically significant for baseline HHIE scores (range, 28 to 50).
At 3-month follow-up, trivial improvements from baseline on HHIE scores occurred in the no-treatment and assistive listening device groups (mean change, 2.2 and 4.4 points, respectively), but both types of hearing aids were associated with clinically significant improvements (mean, 17 and 31 points with standard and programmable hearing aids, respectively). Changes in APHAB scores were small in the assistive listening device and no-treatment groups (6 and 3 points, respectively), with no change in Revised QDS scores. Although both hearing aid groups had greater improvements in hearing-related outcomes than the no-treatment and assistive listening device groups, these were baseline differences between groups, and results are subject to additional confounding because patients were randomly assigned separately on the basis of eligibility for free hearing aids.
In another fair-quality crossover trial (n ϭ 80), a subgroup of patients not using hearing aids at enrollment (mean pure-tone threshold hearing loss of 37 dB and mean HHIE score of 30) found no clear differences between hearing aids, an assistive listening device, or both and no amplification on HHIE scores and other measures of function or quality of life (18) . A poor-quality trial (n ϭ 133) found that older adults who were randomly assigned to hearing aids did not experience improvement in Geriatric Depression Scale scores at 6 months and did not report results in adults randomly assigned to no hearing aids (20) .
in hearing-related function did not differ. Hearing aid use at 1 year was less than 10% in all groups in the trial, and the trial was not powered to assess improvements in hearing-related function. The trial also restricted enrollment to veterans who were eligible for free hearing aids, three quarters of whom reported perceived hearing loss. Therefore, results are likely to be most applicable to populations with a high prevalence of perceived hearing loss, in settings where treatment cost is not a barrier.
Good evidence suggests that common screening tests are useful for identifying patients at higher risk for hearing loss. A challenge in understanding diagnostic accuracy is that studies used different thresholds and criteria to define hearing loss. The clinical relevance of detecting mild (25 to 40 dB) hearing loss as it pertains to effectiveness of screening is also uncertain, because the only trial showing benefits of hearing aids enrolled patients with screening-detected hearing loss greater than 40 dB (19) . Relatively simple tests, such as the whispered voice test at 2 feet or single-question screening, regarding perceived hearing loss seem to be nearly as accurate as a more detailed hearing loss questionnaire or a hand-held audiometric device. A negative screening result based on a hand-held audiometric device may be particularly useful for ruling out hearing loss greater than 40 dB. The choice of which screening test to use may depend in part on cost or convenience. For the whispered voice test, an important consideration is the need for standardized and consistent administration. Although the finger rub and the watch tick tests may be easier to standardize, both were evaluated in only 1 study (23) .
Our conclusions regarding diagnostic accuracy are generally in accord with another recent systematic review (7) . It estimated stronger likelihood ratios for the whispered voice test, largely because it was conducted before the publication of a recent good-quality study (23) that reported substantially weaker estimates. The other review also pooled LR estimates, included studies (5, 47, 48) that analyzed the same populations reported in other studies (33, 37) , included studies that we considered to be less applicable to U.S. primary care settings (49, 50), and did not include studies that we deemed relevant (28, 34) .
Evidence on the efficacy of treatments of screeningdetected hearing loss is limited. One good-quality RCT found that hearing aids resulted in near-normalization of hearing-related quality of life in a subgroup of patients identified by screening, based on hearing loss greater than 40 dB using a hand-held audiometric device (19) . Because the trial was conducted in a VA medical center and almost exclusively enrolled white men, its generalizability to other settings may be limited. Two fair-quality RCTs found no clear differences in hearing-related quality-of-life outcomes between amplification and no treatment in patients with milder baseline hearing loss (18, 21) .
We did not find direct evidence on harms of screening or treatments with hearing aids. In community-based and primary care populations, rates of false-positive detection of hearing loss greater than 25 dB ranged from 5% to 41% (25, 28, 30, 33, 36) . However, harms of screening are probably minimal because screening tests and the reference standard (audiometric testing) are noninvasive, and hearing aids are not known to be associated with serious adverse events. No study has tested the hypothesis that hearing aid use might lead to further deterioration in patients with severe to profound hearing loss due to the increased amplification required (51) .
Our evidence review has limitations. First, evidence was very limited for benefits and harms of screening for and treatments of hearing loss, making it difficult to reach strong conclusions. We excluded non-English-language studies, which could introduce language bias, although we identified no relevant non-English-language studies in literature searches or when reviewing reference lists. Finally, many studies evaluated diagnostic accuracy of screening tests in populations recruited from specialty settings, which could limit their generalizability to primary care settings (14) .
Hearing loss is very common in older adults. Additional research is needed on the effectiveness of screening in typical primary care settings, the optimal age at which to start screening, and the severity of hearing loss that is likely to benefit from hearing aids to help define optimal screening test thresholds and methods. Because the effectiveness of any hearing screening strategy will depend on how likely persons who might benefit from hearing aids are to actually use them, research is needed on effective methods for enhancing follow-up rates and uptake of recommended treatments (including more effective treatments or increased usability of hearing aids) after screening. 
APPENDIX: ADDITIONAL DETAILS ON STUDY SELECTION
The target sample was persons aged 50 years or older who were evaluated in primary care settings and did not have diagnosed hearing loss, including those with and without selfperceived hearing problems. The target condition for this review was chronic sensorineural hearing loss, the most common type of hearing loss in older adults (1) . Reference criteria for hearing loss vary but generally define hearing loss as decreased tonal perception on pure-tone audiometric testing at frequencies between 500 and 4000 Hz, the most important for speech processing (38, 51, 52) . Mild hearing loss is frequently considered the inability to hear tones within this range at 25 dB or less and moderate hearing loss as inability to hear them at 40 dB or less. Although hearing problems can occur despite normal tonal perception (2), hearing loss is generally defined on the basis of pure-tone audiometric testing because the primary treatment is signal amplification. For screening tests, we focused on clinical tests (detection of a whispered voice, finger rub, or watch tick), a single question (for example, "Do you have difficulty with your hearing?), questionnaires (for example, the HHIE-S, a 10-item self-administered questionnaire) (31, 38) , and hand-held audiometric devices (for example, AudioScope, a portable instrument consisting of an otoscope with a built-in audiometer). The purpose of all screening tests is to identify people at higher risk for hearing loss who should be referred for formal audiometry. We excluded the Rinne and Weber tests because their main purpose is to distinguish conductive from sensorineural hearing loss. For treatments, we focused on hearing aids and assistive listening devices (instruments with an off-ear microphone to pick up and amplify targeted sounds). Outcomes of interest were hearing-related function, quality of life, and adverse events related to screening or treatment. We excluded congenital hearing loss, sudden hearing loss, and hearing loss due to recent occupational or other exposure. We also excluded conductive hearing loss because it is uncommon in older adults (1). 
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